Hairy cell leukemia: Survival and relapse: Long-term follow-up of purine analog-based therapy and approach for relapsed disease

Martin S. Tallman*, Anaadriana Zakarija

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Since its initial description approximately 50 years ago, there has been an impressive evolution in therapies for hairy cell leukemia. Long-term follow-up with 2-cholorodeoxyadenosine and 2′-deoxycoformycin demonstrates that both agents result in a high complete remission rate and overall survival. Relapse rates appear to be between 20% and 30%. Therapeutic strategies for patients with relapsed disease include retreatment with a purine analog, rituximab, or the anti-CD22 pseudomonas exotoxin A immunoconjugate, BL-22.

Original languageEnglish (US)
Pages (from-to)99-103
Number of pages5
JournalTransfusion and Apheresis Science
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Hairy cell leukemia: Survival and relapse: Long-term follow-up of purine analog-based therapy and approach for relapsed disease'. Together they form a unique fingerprint.

  • Cite this